Archive - August 2018
Daily Brief: Biosimilar Herceptin can’t make Perjeta cost effective and more
Armoured CAR ‘could overwhelm solid tumour resistance’
Don’t miss the 7 September deadline
News of the inaugural Medical & Scientific Excellence Awards is spreading fast
Novo spends $800m to buy biotech and ‘glucose responsive insulin’ tech
NICE sticks with ‘no’ for use of Perjeta after breast cancer surgery
Closing soon – ENTER NOW
Novo buys UK group Ziylo